{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-069983","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.211214+00:00","generated_at":"2026-06-11T05:40:53.660991+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Blue Water Biotech CEO resigns; interim CEO appointed; Audit Committee reviews employee expenditures","bullets":["Joseph Hernandez resigned as Chairman, CEO, and Board member, effective Aug 16, 2023.","James Sapirstein appointed Interim Executive Chairman effective Sept 30; receives $25k/month.","CFO Jon Garfield appointed interim principal executive officer until Sapirstein's appointment.","Audit Committee commenced independent review of company employee expenditures and classification."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-069983","json":"https://secwatch.observer/filing/0001213900-23-069983.json","markdown":"https://secwatch.observer/filing/0001213900-23-069983.md","text":"https://secwatch.observer/filing/0001213900-23-069983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/ea184059-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:40:53.660991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22b97c3534","claim":"Joseph Hernandez resigned as Chairman, Chief Executive Officer, and Member of the Board of Directors at Onconetix, Inc..","evidence_excerpt":"Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman, Chief Executive Officer, and Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"24cf9665d5","claim":"James Sapirstein was appointed as Interim Executive Chairman at Onconetix, Inc..","evidence_excerpt":"the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"9702cca828","claim":"Jon Garfield was appointed as Chief Financial Officer and interim principal executive officer at Onconetix, Inc..","evidence_excerpt":"Effective August 16, 2023, Board has appointed Jon Garfield, the Company’s Chief Financial Officer, to serve as the Company’s interim principal executive officer during the pendency of Mr. Sapirstein’s appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023069983/0001213900-23-069983-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and interim principal executive officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}